Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors, stimulants |
Mechanism E2F1 inhibitors(Transcription factor E2F1 inhibitors), MUC4 inhibitors(mucin 4, cell surface associated inhibitors), PTEN stimulators(PTEN stimulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC10H12O2 |
InChIKeyKEQHJBNSCLWCAE-UHFFFAOYSA-N |
CAS Registry490-91-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gingivitis | Phase 1 | Saudi Arabia | 01 Sep 2022 | |
Hormone receptor positive breast cancer | Preclinical | Egypt | 16 Sep 2021 | |
Hormone receptor positive breast cancer | Preclinical | - | 16 Sep 2021 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 01 Jul 2018 | |
Kidney Neoplasms | Preclinical | South Korea | 15 Jul 2016 | |
Triple Negative Breast Cancer | Preclinical | United States | 15 Jul 2016 | |
Diffuse Large B-Cell Lymphoma | Preclinical | Saudi Arabia | 15 Apr 2012 | |
Primary Effusion Lymphoma | Preclinical | United States | 01 May 2009 | |
Primary Effusion Lymphoma | Preclinical | Saudi Arabia | 01 May 2009 | |
Prostatic Hyperplasia | Preclinical | United States | 01 May 2009 |
Not Applicable | - | bgjqzizwtd(auhgvusmgt) = lkzvoocati mcntuaioxh (bkeokixxnm ) View more | - | 01 Jul 2017 | |||
bgjqzizwtd(auhgvusmgt) = wxcnfaashz mcntuaioxh (bkeokixxnm ) View more |